AstraZeneca, Merck eye $1 billion boost from cancer drug success

LONDON (Reuters) - AstraZeneca's oncology business received a boost on Wednesday as results of a clinical trial showed its drug Lynparza helped women with ovarian cancer live longer without their disease worsening when given as a first-line treatment.

from Reuters: Health News https://ift.tt/2Iwcn1f